Compare ELA & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELA | PRTC |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | 90 |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.7M | 400.2M |
| IPO Year | 1995 | N/A |
| Metric | ELA | PRTC |
|---|---|---|
| Price | $17.07 | $18.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 161.8K | 3.3K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.38 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $241,021,362.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.54 | N/A |
| P/E Ratio | $30.46 | ★ $8.09 |
| Revenue Growth | ★ 33.62 | N/A |
| 52 Week Low | $5.33 | $14.50 |
| 52 Week High | $18.29 | $19.92 |
| Indicator | ELA | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 69.02 |
| Support Level | $16.09 | $18.07 |
| Resistance Level | $18.29 | $19.49 |
| Average True Range (ATR) | 0.74 | 0.51 |
| MACD | -0.09 | 0.40 |
| Stochastic Oscillator | 54.45 | 95.66 |
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.